Nicotinamide Mononucleotide Market
The market for Nicotinamide Mononucleotide was estimated at $721 million in 2024; it is anticipated to increase to $1.09 billion by 2030, with projections indicating growth to around $1.53 billion by 2035.
Global Nicotinamide Mononucleotide Market Outlook
Revenue, 2024
Forecast, 2034
CAGR, 2025 - 2034
The Nicotinamide Mononucleotide industry revenue is expected to be around $772.6 million in 2025 and expected to showcase growth with 7.1% CAGR between 2025 and 2034. The increasing demand for Nicotinamide Mononucleotide is an indication of its rising importance in the ever evolving healthcare field due to its numerous health advantages related to aging and unique molecular structure dynamics that are changing perspectives in both health supplements and pharmaceutical industries today and tomorrow. A result of ongoing research progress and manufacturing advancements alongside consumers growing emphasis, on well being and health trends.
Nicotinamide Mononucleotide plays a role in various biological functions by potentially aiding in fighting age related ailments and improving cellular energy production and DNA repair processes. It is present in a range of foods like broccoli, cucumber, cabbage edamame and avocados. However the recent increase in its popularity stemmed from its incorporation, into supplements and products aimed at combating aging signs.
Market Key Insights
- The Nicotinamide Mononucleotide market is projected to grow from $721.4 million in 2024 to $1.43 billion in 2034. This represents a CAGR of 7.1%, reflecting rising demand across Ageing & Longevity Research, Metabolic Health Improvement and Cardiovascular Health Management.
- Elysium Health, Genex Formulas, RevGenetics are among the leading players in this market, shaping its competitive landscape.
- U.S. and China are the top markets within the Nicotinamide Mononucleotide market and are expected to observe the growth CAGR of 4.6% to 6.8% between 2024 and 2030.
- Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 8.2% to 9.8%.
- Transition like Growing Health Awareness has greater influence in U.S. and China market's value chain; and is expected to add $38 million of additional value to Nicotinamide Mononucleotide industry revenue by 2030.
- The Nicotinamide Mononucleotide market is set to add $711 million between 2024 and 2034, with manufacturer targeting Dietary Supplement & Cosmetics Application projected to gain a larger market share.
- With Increasing demand in anti-aging segment, and Therapeutic applications in chronic disorders, Nicotinamide Mononucleotide market to expand 99% between 2024 and 2034.